What we are learning from CAR-T implementation: Development, regulatory and clinical practices

0Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

The last decade has witnessed a significant advancement in medical science and technologies. The cell and gene therapies represent remarkable outcomes of such progress achieved in a very short timeframe. The COVID-19 pandemic has created roadblocks for patients to access hospitals for diagnosis and treatments since the onset of its first-wave. On the contrary, this one-year leap has witnessed unprecedented technological advances, especially in terms of mRNA-based therapies and their regulations. The present review focuses on CAR-T as a model with all key attributes and implications in complicated chains from early science to a variety of models and trends in clinical practice.

Cite

CITATION STYLE

APA

Samsonov, M. Y., & Lomonosov, A. M. (2021). What we are learning from CAR-T implementation: Development, regulatory and clinical practices. Cellular Therapy and Transplantation, 10(2), 26–36. https://doi.org/10.18620/CTT-1866-8836-2021-10-2-26-36

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free